• Tuberculosis and Respiratory Diseases
• /
• 제73권3호
• /
• pp.137-142
• /
• 2012

In the last several years, we have made slow but steady progress in understanding molecular biology of lung cancer. This review is focused on advances in understanding the biology of lung cancer that have led to proof of concept studies on new therapeutic approaches. The three selected topics include genetics, epigenetics and non-coding RNA. This new information represents progress in the integration of molecular mechanisms that to identify more effective ways to target lung cancer.

• Journal of Chest Surgery
• /
• 제54권4호
• /
• pp.258-262
• /
• 2021

Mediastinal lymph node dissection is an important part of lung cancer surgery that provides accurate nodal staging and may improve survival outcomes. The minimally invasive approach, such as video-assisted thoracic surgery (VATS) lobectomy for patients with non-small cell lung cancer, has become a standard operation worldwide. VATS mediastinal lymph node dissection should be thorough and accurate to ensure the completeness of lung cancer surgery. Herein, the author describes techniques for VATS mediastinal lymph node dissection.

• Journal of Chest Surgery
• /
• 제37권2호
• /
• pp.184-187
• /
• 2004

식도와 폐에 동시성 중복암이 발생하는 경우는 드물다. 우폐 하엽과 흉부 식도에 원발성 편평상피세포암이 발생한 75세 남자 환자에 대해 우폐 하엽 절제술과 Ivor Lewis 술식을 동시에 시행하였다. 좌폐 상엽의 편평상피세포암으로 좌폐 상엽 절제술을 시행했던 69세 남자 환자에서 4개월 후 흉부 식도에 발생한 편평상피세포암에 대해 Ivor Lewis 술식을 시행하였다. 상기 2명의 환자는 수술 후 각각 10개월, 24개월째이며 재발 없이 잘 지내고 있다. 저자들은 식도와 폐에 발생한 동시성 중복암 2예에 대해 완전 절제를 시행하여 좋은 결과를 얻었기에 문헌고찰과 함께 보고하는 바이다.

• Journal of Chest Surgery
• /
• 제20권3호
• /
• pp.598-602
• /
• 1987

Primary sarcomas of the lung are rare malignant neoplasms which have usually been classified as fibrosarcomas or leiomyosarcomas. Only 10 cases of primary malignant fibrous histiocytoma [MFH] of the lung have previously been reported in the literatures. The histomorphology of the MFH is marked by their extensive cellular variability, nuclear atypia, abnormal mitotic figures and storiform arrangement of the cells. Recently, we experienced a case of MFH, arising in the parenchyme of lung in 66-year-old male patient, and treated with surgical intervention. So we firstly reported it with review of literatures.

• Tuberculosis and Respiratory Diseases
• /
• 제75권6호
• /
• pp.236-237
• /
• 2013

Many attempts have been made to find genetic abnormalities inducing carcinogenesis after the development of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor targeting EGFR in lung cancer. New target therapies have been already commercialized and studied along with the recent discovery of gene rearrangement involved in the carcinogenic process of non-small cell lung cancer. This study aims to investigate anplastic lymphoma kinase, c-ros oncogene 1, and receptor tyrosine kinase, in particular.

• Asian Pacific Journal of Cancer Prevention
• /
• 제13권7호
• /
• pp.3253-3258
• /
• 2012

Objective: To evaluate the efficacy and safety of whole brain radiotherapy (WBRT) plus chemotherapy versus WBRT alone for treating brain metastases (BM) from lung cancer by performing a meta-analysis based on randomized controlled trials (RCTs). Methods: The PubMed, Embase, CENTRAL, ASCO, ESMO, CBM, CNKI, and VIP databases were searched for relevant RCTs performed between January 2000 and March 2012. After quality assessment and data extraction, the meta-analysis was performed using the RevMan 5.1 software, with funnel plot evaluation of publication bias. Results: 19 RCTs involving 1,343 patients were included. The meta-analyses demonstrated that compared to WBRT alone, WBRT plus chemotherapy was more effective with regard to the objective response rate (OR = 2.30, 95% CI = 1.79 - 2.98; P < 0.001); however, the incidences of gastrointestinal reactions (RR = 3.82, 95% CI = 2.33 - 6.28, P <0.001), bone marrow suppression (RR = 5.49, 95% CI = 3.65 - 8.25, P < 0.001), thrombocytopenia (RR = 5.83, 95% CI = 0.39 - 86.59; P = 0.20), leukopenia (RR = 3.13, 95% CI = 1.77 - 5.51; P < 0.001), and neutropenia (RR = 2.75, 95% CI = 1.61 - 4.68; P < 0.001) in patients treated with WBRT plus chemotherapy were higher than with WBRT alone. There was no obvious publication bias detected. Conclusion: WBRT plus chemotherapy can obviously improve total efficacy rate, butalso increases the incidence of adverse reactions compared to WBRT alone. From the limitations of this study, more large-scale, high-quality RCTs are suggested for further verification.

• Journal of Chest Surgery
• /
• 제25권10호
• /
• pp.1076-1081
• /
• 1992

The sclerosing hemangioma of the lung is rare, benign neoplasms, which are usually solitary, Althoughh their histologic apperances are distinct and well-defined, their histogenesis is uncertain. We experienced a typical lesion of pulmonary sclerosing hemangioma clinically and histologically, which was removed from the right lobe of 64-year-old female. We disccused histogenesis, microscopic feature and progress of the sclerosing hemangioma.

• Journal of Chest Surgery
• /
• 제37권12호
• /
• pp.1032-1035
• /
• 2004

미만간질폐병에서 확진을 위해 개흉 폐 생검을 한다. 미만간질페병은 많은 경우에 있어서 페암과 병발한다. 미만간질페병환자의 폐생검후 발견된 폐 선암 증례 1예를 통해서, 미만간질폐병과 폐암의 상관관계의 고찰과, 폐 생검시 부위 및 생검 횟수에 대한 일반적 기준의 정립에 관해서 논의해보고자 문헌 고찰과 함께 보고한다.

• Tuberculosis and Respiratory Diseases
• /
• 제79권2호
• /
• pp.58-69
• /
• 2016

Lung cancer causes the most cancer deaths in Korea. Although the smoking rate has begun to decrease, the prevalence of lung cancer is still increasing. We reviewed the national lung cancer registry data and the data published about lung cancer in Korea. In 2012, the crude incidence rate of lung cancer was 43.9 per 100,000. The age-standardized mortality rate of lung cancer was 19.8 per 100,000. The 5-year relative survival rate for lung cancer was 11.3% from 1993 to 1995 and increased to 21.9% in the period from 2008 to 2012. Lung cancer occurring in never-smokers was estimated to increase in Korea. Adenocarcinoma is steadily increasing in both women and men and has replaced squamous cell carcinoma as the most common type of lung cancer in Korea. In patients with adenocarcinoma, the frequency of EGFR mutations was 43% (range, 20%-56%), while that of the EMK4-ALK gene was less than 5%.

• Tuberculosis and Respiratory Diseases
• /
• 제77권2호
• /
• pp.60-64
• /
• 2014

MicroRNAs (miRNAs) are a class of small noncoding RNAs that modulate target gene activity, and are aberrantly expressed in most types of cancer as well in lung cancer. A miRNA can potentially target a diverse set of mRNAs; further, it plays a critical role in lung tumorigenesis as well as affects patient outcome. Previous studies focused mainly on abnormal miRNAs expressions in lung cancer tissues. Interestingly, circulating miRNAs were identified in human plasma and serum in 2008. Since then, considerable effort has been directed to the study of circulating miRNAs as one of the biomarkers of lung cancer. miRNAs expression of tissues and blood in lung cancer patients is being analyzed by more researchers. Recently, to overcome the high false-positivity of low-dose chest computed tomography scan, miRNAs in lung cancer screening are being investigated. This article summarizes the recent researches regarding clinical applications of miRNAs in the diagnosis and management of lung cancer.